JALYN Drug Patent Profile

Which patents cover Jalyn, and what generic alternatives are available?

Jalyn is a drug marketed by Waylis Therap and is included in one NDA.

The generic ingredient in JALYN is dutasteride; tamsulosin hydrochloride. There are eighteen drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the dutasteride; tamsulosin hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Jalyn

A generic version of JALYN was approved as dutasteride; tamsulosin hydrochloride by PH HEALTH on February 26^th, 2014.

Summary for JALYN

US Patents:	0
Applicants:	1
NDAs:	1

Paragraph IV (Patent) Challenges for JALYN

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
JALYN	Capsules	dutasteride; tamsulosin hydrochloride	0.5 mg/0.4 mg	022460	1	2010-10-26

US Patents and Regulatory Information for JALYN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Waylis Therap	JALYN	dutasteride; tamsulosin hydrochloride	CAPSULE;ORAL	022460-001	Jun 14, 2010	AB	RX	Yes	No

International Patents for JALYN

See the table below for patents covering JALYN around the world.

Country	Patent Number	Title	Estimated Expiration
Hong Kong	1004334
Canada	2449679	ANDROSTENONES (ANDROSTENONES)
Greece	3026144
China	1041939
Bulgaria	62363
Germany	69407978

Supplementary Protection Certificates for JALYN

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0719278	PA2003007,C0719278	Lithuania		PRODUCT NAME: DUTASTERIDUM (17BETA-N(2,5-BIS(TRIFLUORMETIL)FENILKARBAMOIL-4-AZA-5ALFA-ANDROST-1-EN-3-ONAS), PASIRINKTINAI FARMACISKAI TINKAMO SOLVATO FORMOJE; REGISTRATION NO/DATE: 03/8183/7 20030909
0719278	23/2003	Austria		PRODUCT NAME: DUTASTERIDE, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ANNEHMBAREN SOLVATES; NAT. REGISTRATION NO/DATE: 1-24844, 1-24845 20030217; FIRST REGISTRATION: SE 17871, 17872 20020719
0719278	PA2003007	Lithuania		PRODUCT NAME: DUTASTERIDUM (17BETA-N(2,5-BIS(TRIFLUORMETIL)FENILKARBAMOIL-4-AZA-5ALFA-ANDROST-1-EN-3-ONAS), PASIRINKTINAI FARMACISKAI TINKAMO SOLVATO FORMOJE; REGISTRATION NO/DATE: 03/8183/7 20030909
0719278	SPC009/2005	Ireland		SPC009/2005: 20060316, EXPIRES: 20170718
0719278	300122	Netherlands
0719278	PA 2003 007, C 0719278 /L	Lithuania

JALYN Market Analysis and Financial Projection

Last updated: February 3, 2026

What is JALYN and its Approved Use?

JALYN is a fixed-dose combination drug—including dutasteride (0.5 mg) and tamsulosin (0.4 mg)—developed by GlaxoSmithKline (GSK). It is primarily approved for the treatment of benign prostatic hyperplasia (BPH) with or without urinary symptoms. JALYN was launched in several markets after FDA approval in 2013.

How Do Market Dynamics Affect JALYN’s Investment Outlook?

Market Size and Growth

The global BPH drug market was valued at approximately $4.5 billion in 2022 and is projected to reach around $6 billion by 2030, growing at a compound annual growth rate (CAGR) of roughly 4.2%[1]. The prevalence of BPH increases with age, affecting about 50% of men over 50 and up to 90% over 80[2].

Competitive Landscape

JALYN faces competition primarily from monotherapies such as:

• Tamsulosin (Flomax)
• Dutasteride (Avodart)
• Finasteride (Proscar)

Combination therapies are gaining popularity for their efficacy, but JALYN’s fixed-dose formulation distinguishes it. Other combination drugs include:

• Dutasteride + Tamsulosin generics
• Other branded combinations (e.g., Jalyn equivalent in certain regions)

Patent and Regulatory Status

GSK holds patent protections until roughly 2030 in key markets. Patent challenges or expiration could allow generic competition, pressuring pricing. Regulatory developments, such as new guidelines on BPH management, can influence demand.

Market Penetration and Adoption

JALYN’s adoption hinges on physician prescribing behaviors and patient acceptance. Its fixed-dose simplifies treatment compared to separate drug administration, potentially enhancing adherence. However, physician familiarity with monotherapies and cost factors impact market share.

Financial and Investment Fundamentals

Revenue and Market Share

GSK reported significant sales of JALYN before generic competition emerged in some regions. Exact numbers are not publicly broken down but are integrated into urology product portfolios. Market penetration remains moderate in established markets like the US and Europe but limited in emerging markets due to pricing and access.

Regulatory Risks and Patent Challenges

Patent expiries threaten exclusivity. A patent lawsuit or challenge from generics could lead to early market entry of cheaper alternatives, reducing profit margins.

Development Pipeline and Line Extensions

Therapies targeting BPH, such as selective alpha-blockers or 5-alpha reductase inhibitors, influence JALYN’s outlook. GSK’s pipeline includes next-generation drugs for QOL improvement, but no direct JALYN alternatives are publicly in late-stage development.

Pricing and Reimbursement Policies

Drug pricing varies globally. Payors favor generics for cost savings, pressuring branded drugs like JALYN. Reimbursement rates influence market viability, especially in low-income regions.

Investment Risks and Opportunities

Risks

• Patent expiration risks reduce pricing power.
• Competition from generics and evolving treatment guidelines.
• Regulatory changes affecting drug approval or reimbursement.
• Market saturation in mature regions.

Opportunities

• Increasing prevalence of BPH driven by aging populations.
• Adoption of fixed-dose combination therapy for improved patient compliance.
• Expansion into emerging markets with growing healthcare access.
• Potential lifecycle extension through new formulations or indications.

Summary of Key Data

Aspect	Data
Global BPH market (2022)	$4.5 billion
Projected market (2030)	~$6 billion, CAGR 4.2%
US Market Penetration	Moderate; affected by generics
Patent expiry	Estimated 2030 in major markets
Market growth drivers	Aging population, increasing BPH prevalence

Key Takeaways

• JALYN benefits from the efficacy of a combination therapy with high patient compliance.
• Market dynamics favor growth, but patent expiration and competition could significantly erode margins.
• GSK's pipeline and pipeline extensions are crucial for sustaining long-term value.
• Generics pose the primary threat to revenue, especially post-patent expiry.
• Market expansion opportunities exist in emerging economies with rising healthcare access.

Frequently Asked Questions

1. How does JALYN compare to monotherapies in efficacy?

Clinical trials show JALYN has superior effectiveness in symptom relief due to the synergistic effects of dutasteride and tamsulosin. It reduces both prostate size and urinary symptoms more rapidly than monotherapies.

2. When is the patent for JALYN expected to expire?

Patent protections are expected to last until around 2030 in major markets, but this can vary due to legal challenges or regional differences.

3. What are the main regulatory hurdles for JALYN?

JALYN currently has regulatory approval; challenges include patent litigation and evolving treatment guidelines that may favor alternative therapies or generic competition.

4. Is there potential for JALYN in markets outside of the US and Europe?

Yes. Emerging markets, such as China and India, show rising BPH prevalence and increasing healthcare spending. Market entry depends on local regulatory approvals and pricing strategies.

5. How could future developments in BPH treatment impact JALYN?

Innovation in targeted therapies, minimally invasive procedures, and personalized medicine could reduce reliance on pharmacologic treatments like JALYN, affecting long-term sales.

---

References

[1] MarketResearch.com, "Global Benign Prostatic Hyperplasia (BPH) Market," 2022.

[2] Roehrborn, C. et al., "Benign prostatic hyperplasia: management," The Lancet, 2010.

[3] U.S. Food and Drug Administration, "JALYN approval letter," 2013.

[4] GSK Annual Reports, 2022.